Press Releases
October 26, 2011
First Patient Enrolled and Randomized in Medtronic's SYMPLICITY HTN-3 U.S. Clinical Trial to Evaluate the Symplicity Renal Denervation System. Please visit www.SymplifyBPTrial.com for more information.July 11, 2011
FDA Approves Medtronic's SYMPLICITY HTN-3 U.S. Clinical Trial Protocol for Study of Novel Treatment for High Blood PressureJanuary 13, 2011
Medtronic Completes Acquisition of ArdianNovember 22, 2010
Medtronic Signs Agreement to Acquire ArdianNovember 17, 2010
Medtronic’s Catheter-Based Treatment for Hypertension Demonstrates Substantial and Sustained Blood Pressure Reduction in Landmark Randomized Clinical TrialNovember 17, 2010
Ardian’s Catheter-Based System for Renal Denervation Now Commercially Available in AustraliaJune 21, 2010
Ardian® Demonstrates 2-Year Durability of Blood Pressure Reduction in Hypertension Patients Treated with Symplicity® Catheter System™June 3, 2010
Ardian® Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for HypertensionSeptember 25, 2009
Ardian® Demonstrates Durable Blood Pressure Reduction in Hypertension Patients Treated with Symplicity® Catheter System™March 30, 2009
Ardian® Demonstrates Substantial and Sustained Blood Pressure Reduction in Hypertension Patients Treated with Symplicity® Catheter System™March 23, 2009
Ardian Completes $47 Million Financing Led by Medtronic to Develop Hypertension TreatmentFurther information available at wwwp.medtronic.com/Newsroom/
